Biovie Inc. · NASDAQ:BIVI
Biovie — CTAD conference call 2023
9 slides from Biovie's conference presentation, Nov 1, 2023
Slide 1: Discussion of Data Presented at CTAD
Discussion of Data Presented at CTAD Conference Call • November 1, 2023
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains statements about BioVie’s future expectations, plans, strategies and prospects which constitute forward-looking statements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Refo
Slide 3: Blinded data presented at CTAD
Blinded data presented at CTAD • Data presented in the following slides are based on evaluable blinded data as of October 18, 2023 • The data presented are currently undergoing cleaning and verification. The results may change post cleaning and database lock • Data unblinding and reveal targeted for
Slide 4: Consistent patterns of improvements and worsening across all cognitive and functional assessments
Blinded data Consistent patterns of improvements and worsening across all cognitive and functional assessments ADAS-Cog12 change ADCS-clinician global Mini-Mental State Exam Clinical Dementia Rating CDR Sum of Boxes AD Composite Score Activities of Daily Living (MMSE) change (CDR) change (CDR SB) ch
Slide 5: Reduced Amyloid burden observed
Blinded data Reduced Amyloid burden observed The PrecivityAD® test identifies whether a patient is likely to have the presence or absence of amyloid plaques in the brain • Relies on precise quantitation of Amyloid Beta 42/40 ratio (Aβ 42/40) and detection of Apolipoprotein E proteotype (equivalent t
Slide 6: Imaging substudy also points to reduced Amyloid burden
Blinded data Imaging substudy also points to reduced Amyloid burden • FDG PET was analyzed in 21 evaluable subjects with baseline and week 30 data • Sum of ROIs in regional cortical FDG-PET standard uptake value ratios (SUVR) increased in 10/21 subjects • If unblinded data concur with this, it would
Slide 7: Imaging substudy also points to increased brain volumes
Blinded data Imaging substudy also points to increased brain volumes • vMRI was analyzed in 23 evaluable subjects with baseline and V10 data • Median volumes increased in hippocampus and amygdala vMRI Hippocampus volume vMRI Amygdala volume 400 200 Hippocampus cfb μL Amygdala cfb μL 200 100 0 0 -200
Slide 8: Confirmation of inflammatory and metabolic impact
Blinded data Confirmation of inflammatory and metabolic impact • Improvements in insulin signaling without any reports of hypoglycemia • If unblinded data concur with this, it would also be evidence of target engagement TNFα 2 0 Insulin HOMA2-%B HOMA2-%S MAGE Change from Baseline +1.9 mIU/mL, * +13.
Slide 9: Thank You
Thank You